carboplatin

(redirected from Paraplatin)
Also found in: Medical.

carboplatin

[¦kär·bō′plat·ən]
(medicine)
A platinum coordination compound and anticancer agent used for advanced gynecologic malignancies, especially ovarian tumors, and for head and neck cancers and lung cancers.
References in periodicals archive ?
The prescription drugs mentioned in the complaint include: -- Alkeran -- Blenoxane -- Cytoxan -- Etopophos -- Kytril -- Navelbine -- Paraplatin -- Procrit -- Remicade -- Rubex -- Taxol -- Vepesid -- Zofran -- Zoladex -- Zovirax
The increase in volume of drug per patient will likely arise from the introduction of novel immunotherapeutic and antiangiogenic agents administered concurrently with or following treatment with the current gold-standard therapy of carboplatin (Bristol-Myers Squibb's Paraplatin, generics) combined with paclitaxel (Bristol-Myers Squibb's Taxol, generics)," said Jude Nelson, analyst at Decision Resources, Inc.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the adjuvant treatment of stage IB, II, and IIIA non-small-cell lung cancer (NSCLC), the highest proportion of surveyed managed care organizations' (MCO) pharmacy directors select paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) and docetaxel (Sanofi-Aventis's Taxotere)/cisplatin* as having the best overall clinical profile when compared to other currently-available therapies.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of second-line platinum sensitive advanced ovarian cancer, one-third of surveyed oncologists indicate that paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) has the best overall clinical profile when compared to other currently available therapies.
He is a highly experienced senior pharmaceutical sales executive who led several successful launches of blockbuster oncology drugs, including Taxol and Paraplatin.
According to the new report entitled Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy Continues to Be Most Efficacious; physicians indicate that the most promising emerging therapies for the treatment of non-small-cell lung cancer will not match the current gold- standard regimen comprising Roche/Genentech/Chugai's Avastin, Bristol-Myers Squibb's Taxol, and Bristol-Myers Squibb's Paraplatin.
Clinical data and expert opinion show that Roche/Genentech/Chugai's Avastin (bevacizumab) plus the regimen of paclitaxel (Bristol-Myers Squibb's Taxol, generics) and carboplatin (Bristol- Myers Squibb's Paraplatin, generics) has advantages in this attribute over the combination of paclitaxel/carboplatin, the current sales leader in ovarian cancer treatment.
March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.
However, clinical data discussed in the report and interviewed key opinion leaders indicate that current and emerging drugs have a very small advantage over the patient share leader Bristol-Myers Squibb's Etopophos/VePesid, generics plus Bristol-Myers Squibb's Paraplatin, generics on this attribute.
During his tenure with BMS, he was associated with the development and commercialization of several major pharmaceutical products, such as Taxol, Paraplatin, Zerit, Videx, Reyataz, and Abilify.
Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis' Taxotere (docetaxel), Bristol-Myers Squibb's Paraplatin (carboplatin) and Eli Lilly's Gemzar (gemcitabine).
The Pharmacor 2010 findings from the topic entitled Ovarian Cancer which will publish later this month reveal that, since the publication of data last year from the CALYPSO clinical trial, PLD (Centocor Ortho Biotech/Janssen's Doxil, Merck's Caelyx) is being increasingly used in combination with carboplatin (Bristol-Myers Squibb's Paraplatin, generics) as an alternative to paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin in the second-line, platinum-sensitive population.